Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies
Source abstract
Abstract
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated with protein 9) was first identified as a component of the bacterial adaptive immune system and subsequently engineered into a genome-editing tool. The key breakthrough in this field came with the realization that CRISPR/Cas9 could be used in mammalian cells to enable transformative genetic editing. This technology has since become a vital tool for various genetic manipulations, including gene knockouts, knock-in point mutations, and gene regulation at both transcriptional and post-transcriptional levels. CRISPR/Cas9 holds great potential in human medicine, particularly for curing genetic disorders. However, despite significant innovation and advancement in genome editing, the technology still possesses critical limitations, such as off-target effects, immunogenicity issues, ethical considerations, regulatory hurdles, and the need for efficient delivery methods. To overcome these obstacles, efforts have focused on creating more accurate and reliable Cas9 nucleases and exploring innovative delivery methods. Recently, functional biomaterials and synthetic carriers have shown great potential as effective delivery vehicles for CRISPR/Cas9 components. In this review, we attempt to provide a comprehensive survey of the existing CRISPR-Cas9 delivery strategies, including viral delivery, biomaterials-based delivery, synthetic carriers, and physical delivery techniques. We underscore the urgent need for effective delivery systems to fully unlock the power of CRISPR/Cas9 technology and realize a seamless transition from benchtop research to clinical applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · RNA Interference and Gene Delivery · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
School of Medicine, Nazarbayev University, Astana 020000, Kazakhstan
Chemistry Department, Carnegie Mellon University, Pittsburgh, PA 15213, USA
Department of Molecular Physics, Faculty of Chemistry, Lodz University of Technology, 90-924 Łódź, Poland
Funding
Science Committee Ministry of Science and Higher Education of the Republic of Kazakhstan · NSF
References (100+)
Show source-provided references
1. CRISPR-mediated adaptive immune systems in bacteria and archaea10.1146/annurev-biochem-072911-172315 ↗
2. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity10.1038/nature11927 ↗
3. Evolutionary Ecology and Interplay of Prokaryotic Innate and Adaptive Immune Systems10.1016/j.cub.2020.08.028 ↗
4. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery10.1021/acs.chemrev.6b00799 ↗
5. CRISPR-Cas guides the future of genetic engineering10.1126/science.aat5011 ↗
6. CRISPR/Cas9 for genome editing: Progress, implications and challenges10.1093/hmg/ddu125 ↗
7. CRISPR-Cas9 Structures and Mechanisms10.1146/annurev-biophys-062215-010822 ↗
8. CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems10.1146/annurev-micro-091014-104441 ↗
9. Chen, F., Alphonse, M., and Liu, Q. (2020). Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 12.10.1002/wnan.1609 ↗
10. Target specificity of the CRISPR-Cas9 system10.1007/s40484-014-0030-x ↗
11. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing10.1038/nbt.4005 ↗
12. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection10.1016/j.jbiotec.2015.04.024 ↗
13. Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research10.1016/j.omtm.2019.02.008 ↗
14. Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates10.1089/hum.1996.7.3-301 ↗
15. Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion10.1089/hum.1995.6.10-1343 ↗
16. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver10.1073/pnas.91.13.6196 ↗
17. In vivo genome editing in animals using AAV-CRISPR system: Applications to translational research of human disease10.12688/f1000research.11243.1 ↗
18. Triple Vectors Expand AAV Transfer Capacity in the Retina10.1016/j.ymthe.2017.11.019 ↗
19. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice10.1038/nbt.3469 ↗
20. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice10.1089/hum.2013.164 ↗
21. Helper-Dependent Adenoviral Vectors
22. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system10.1038/nature13902 ↗
23. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses10.1089/hum.2015.087 ↗
24. Voets, O., Tielen, F., Elstak, E., Benschop, J., Grimbergen, M., Stallen, J., Janssen, R., van Marle, A., and Essrich, C. (2017). Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells. PLoS ONE, 12.10.1371/journal.pone.0182974 ↗
25. Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing10.1161/CIRCRESAHA.115.304351 ↗
26. Selection-free gene repair after adenoviral vector transduction of designer nucleases: Rescue of dystrophin synthesis in DMD muscle cell populations10.1093/nar/gkv1540 ↗
27. CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice10.1038/mt.2015.192 ↗
28. Maggio, I., Liu, J., Janssen, J.M., Chen, X., and Gonçalves, M.A.F.V. (2016). Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. Sci. Rep., 6.10.1038/srep37051 ↗
29. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas910.1099/vir.0.000139 ↗
30. Wang, Y., and Shao, W. (2023). Innate Immune Response to Viral Vectors in Gene Therapy. Viruses, 15.10.3390/v15091801 ↗
31. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal10.1073/pnas.93.24.13565 ↗
32. Improved system for helper-dependent adenoviral vector production10.1016/j.ymthe.2003.08.014 ↗
33. Adenoviruses as vaccine vectors10.1016/j.ymthe.2004.07.013 ↗
34. Gene therapy with helper-dependent adenoviral vectors: Lessons from studies in large animal models10.1007/s11262-017-1471-x ↗
35. Viral Vectors for Gene Therapy: Translational and Clinical Outlook10.1146/annurev-bioeng-071813-104938 ↗
36. Immune response following intraocular delivery of recombinant viral vectors10.1038/sj.gt.3302030 ↗
37. State-of-the-art lentiviral vectors for research use: Risk assessment and biosafety recommendations10.2174/156652309790031120 ↗
38. Genome-scale CRISPR-Cas9 knockout screening in human cells10.1126/science.1247005 ↗
39. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing10.1038/nbt.2951 ↗
40. Lentivirus pre-packed with Cas9 protein for safer gene editing10.1038/gt.2016.27 ↗
41. Viral integration, fragile sites, and proto-oncogenes in human neoplasia10.1007/BF00195804 ↗
42. Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy10.2174/15665232113136660006 ↗
43. Gene therapy put on hold as third child develops cancer
44. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X110.1172/JCI35700 ↗
45. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X110.1126/science.1088547 ↗
46. Regulators split on gene therapy as patient shows signs of cancer10.1038/419545a ↗
47. The role of liver sinusoidal cells in hepatocyte-directed gene transfer10.2353/ajpath.2010.090136 ↗
48. Ganesan, L.P., Mohanty, S., Kim, J., Clark, K.R., Robinson, J.M., and Anderson, C.L. (2011). Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog., 7.10.1371/journal.ppat.1002281 ↗
49. (2020). High-dose AAV gene therapy deaths. Nat. Biotechnol., 38.
50. Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines10.1126/sciadv.abb8133 ↗
51. Non-viral delivery of CRISPR–Cas9 complexes for targeted gene editing via a polymer delivery system10.1038/s41434-021-00282-6 ↗
52. Cellular uptake of the tat protein from human immunodeficiency virus10.1016/0092-8674(88)90263-2 ↗
53. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein10.1016/0092-8674(88)90262-0 ↗
54. Chances and pitfalls of cell penetrating peptides for cellular drug delivery10.1016/j.ejpb.2004.02.018 ↗
55. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery10.1016/j.addr.2004.10.010 ↗
56. Oral biodrug delivery using cell-penetrating peptide10.1016/j.addr.2011.12.014 ↗
57. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption10.1016/j.jconrel.2008.08.001 ↗
58. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides10.1016/j.jconrel.2009.02.015 ↗
59. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins10.1016/j.ijpharm.2009.07.022 ↗
60. Cell-penetrating peptides: 20 years later, where do we stand?10.1016/j.febslet.2013.04.031 ↗
61. Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges10.1016/j.addr.2016.06.002 ↗
62. Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: Basic science, research tools, and clinical applications10.1021/ar4000554 ↗
63. Cell-penetrating peptides transport therapeutics into cells10.1016/j.pharmthera.2015.07.003 ↗
64. Madani, F., Lindberg, S., Langel, U., Futaki, S., and Graslund, A. (2011). Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys., 2011.10.1155/2011/414729 ↗
65. Cell-Penetrating Peptides: From Basic Research to Clinics10.1016/j.tips.2017.01.003 ↗
66. Mechanism Matters: A Taxonomy of Cell Penetrating Peptides10.1016/j.tibs.2015.10.004 ↗
67. Kalafatovic, D., and Giralt, E. (2017). Cell-Penetrating Peptides: Design Strategies beyond Primary Structure and Amphipathicity. Molecules, 22.10.3390/molecules22111929 ↗
68. Classes of Cell-Penetrating Peptides10.1007/978-1-4939-2806-4_1 ↗
69. Sanders, W.S., Johnston, C.I., Bridges, S.M., Burgess, S.C., and Willeford, K.O. (2011). Prediction of cell penetrating peptides by support vector machines. PLoS Comput. Biol., 7.10.1371/journal.pcbi.1002101 ↗
70. CPPsite: A curated database of cell penetrating peptides10.1093/database/bas015 ↗
71. CPPpred: Prediction of cell penetrating peptides10.1093/bioinformatics/btt518 ↗
72. CPPred-RF: A Sequence-based Predictor for Identifying Cell-Penetrating Peptides and Their Uptake Efficiency10.1021/acs.jproteome.7b00019 ↗
73. Amphipathic peptides and drug delivery10.1002/bip.10585 ↗
74. Intercellular trafficking of VP22-GFP fusion proteins10.1038/sj.gt.3300850 ↗
75. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines10.1002/psc.968 ↗
76. Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression10.1016/0092-8674(89)90417-0 ↗
77. Mechanism of uptake of C105Y, a novel cell-penetrating peptide10.1074/jbc.M509813200 ↗
78. Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity10.3390/ph3123594 ↗
79. Cellular delivery of oligonucleotides by synthetic import peptide carrier10.1023/A:1012188014919 ↗
80. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: Involvement of internalization in the in vivo role of exogenous FGF1210.1074/jbc.M110.198267 ↗
81. The third helix of the Antennapedia homeodomain translocates through biological membranes10.1016/S0021-9258(17)34080-2 ↗
82. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent10.1074/jbc.271.30.18188 ↗
83. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA10.1101/gr.171264.113 ↗
84. Cell-Penetrating Peptide-Mediated Delivery of Cas9 Protein and Guide RNA for Genome Editing10.1007/978-1-4939-6518-2_7 ↗
85. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes10.1038/s41551-023-01032-2 ↗
86. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing10.7150/thno.47007 ↗
87. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA10.1016/j.nano.2016.12.014 ↗
88. Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy10.1038/am.2017.185 ↗
89. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing10.1038/s41565-020-0669-6 ↗
90. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy
91. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing10.1016/j.celrep.2018.02.014 ↗
92. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl310.1073/pnas.2020401118 ↗
93. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels10.1038/s41587-021-00933-4 ↗
94. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice10.1038/s41467-021-26714-w ↗
95. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing10.1038/s41467-020-17029-3 ↗
96. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles10.1073/pnas.1520244113 ↗
97. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo10.1038/nbt.3081 ↗
98. Knocking down barriers: Advances in siRNA delivery10.1038/nrd2742 ↗
99. Lin, M., and Wang, X. (2024). Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment. Pharmaceutics, 16.10.3390/pharmaceutics16010062 ↗
100. Multiple Natural Polymers in Drug and Gene Delivery Systems10.2174/0929867330666230316094540 ↗